南方财经5月26日电,复星医药公告称,控股子公司Henlius Europe GmbH收到欧盟委员会函件,HLX22(重组人源化抗HER2单克隆抗体注射液)用于胃癌治疗获得孤儿药资格认定。HLX22是复星医药自AbClon, Inc.许可引进并自主研发的新型靶向HER2的单克隆抗体,拟用于胃癌和乳腺癌等实体瘤的治疗。此次认定有助于HLX22在欧盟的后续研发、注册及商业化等方面享受政策支持。但新药...
Source Link南方财经5月26日电,复星医药公告称,控股子公司Henlius Europe GmbH收到欧盟委员会函件,HLX22(重组人源化抗HER2单克隆抗体注射液)用于胃癌治疗获得孤儿药资格认定。HLX22是复星医药自AbClon, Inc.许可引进并自主研发的新型靶向HER2的单克隆抗体,拟用于胃癌和乳腺癌等实体瘤的治疗。此次认定有助于HLX22在欧盟的后续研发、注册及商业化等方面享受政策支持。但新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.